Objective: To characterize cerebral microbleeds (CMBs) in lacunar stroke patients in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial and to assess their relationship with recurrent stroke and death, and response to assigned treatment. Methods: SPS3 is a randomized, clinical trial conducted between 2003 and 2011. Patients with recent magnetic resonance imaging (MRI)-documented lacunar infarcts were randomly assigned in a factorial design to target levels of systolic blood pressure (130-149mmHg vs <130mmHg; open label) and to antiplatelet treatment (aspirin/clopidogrel vs aspirin/placebo; double-blinded). The current analysis involves 1,278 trial participants who had a baseline axial T2*-weighted gradient echo MRI sequence allowing for CMB detection. Results: CMBs were present in 30% of 1,278 patients (mean age 5 63 years). Male gender (odds ratio [OR] 5 1.7, 95% confidence interval [CI] 5 1.3-2.3), history of hypertension (OR 5 1.6, 95% CI 5 1.2-2.3), increased systolic blood pressure (1.2 per 20mmHg, 95% CI 5 1.1-1.4), nondiabetic status (OR 5 1.4, 95% CI 5 1.1-1.9), multiple old lacunar infarcts (OR 5 1.9, 95% CI 5 1.5-2.5), and moderate (OR 5 1.7, 95% CI 5 1.2-2.3) or severe (OR 5 4.2, 95% CI 5 3.0-5.9) white matter hyperintensities on MRI were independently associated with CMBs. During a mean follow-up of 3.3 years, overall stroke recurrence was 2.5% per patient-year. Patients with CMBs had an adjusted 2-fold increased risk of recurrent stroke (hazard ratio 5 2.1, 95% CI 5 1.4-3.1). CMBs were not a risk factor for death. There were no statistically significant interactions between CMBs and treatment assignments. Interpretation: Patients with lacunar stroke and CMBs likely harbor a more advanced form of cerebral small vessel disease in need of efficacious therapeutic strategies.
C erebral microbleeds (CMBs) are remnants of prior cerebral microhemorrhages at the level of arterioles and capillaries visualized on blood-sensitive magnetic resonance imaging (MRI) sequences. 1 CMBs have evolved as radiological markers of cerebral small vessel disease (CSVD), representing, most notably, hypertensive arteriopathy (arteriolosclerosis) and/or cerebral amyloid angiopathy (CAA). 2 CMB prevalence is highest in stroke subtypes associated with CSVD and strongly tied to hypertension. 3 Previous studies characterizing CMBs in lacunar stroke have observed prevalence rates ranging from 23 to 54%, [3] [4] [5] [6] [7] [8] [9] [10] with higher prevalence observed within East Asian populations.
CMBs may have important clinical implications as predictors of recurrent stroke and mortality. [11] [12] [13] [14] Data also suggest that stroke patients with CMBs may respond differently to secondary stroke preventative therapies. 15, 16 However, the therapeutic effect of stroke preventive therapies in patients with CMBs has yet to be reported from a randomized controlled trial. Moreover, methodological limitations, imposed by observational design, small sample sizes, and/or absence of clear classification of stroke subtype, hamper our current understanding of CMBs in lacunar stroke and the independent contribution of CMBs to the aforementioned outcomes beyond simply marking underlying CSVD. Accordingly, we sought to characterize CMBs in a well-defined population with symptomatic CSVD by examining lacunar stroke patients within the Secondary Prevention of Small Subcortical Strokes (SPS3) trial and to assess the relationship between CMBs and recurrent stroke and death, as well as response to assigned treatments. We hypothesized that lacunar stroke patients with CMBs would have higher rates of recurrent stroke and death during follow-up and that they would benefit more from aggressive blood pressure management.
Patients and Methods

Study Design
The rationale, design, participant characteristics, and main results of the SPS3 trial have been reported elsewhere. [17] [18] [19] [20] In brief, SPS3 was an international randomized clinical trial investigating optimal blood pressure target and antiplatelet regimen in 3,020 patients with recent, symptomatic, MRI-confirmed lacunar infarcts. Eligible participants were patients aged 30 years with a recent (180 days) MRI-documented lacunar infarct, without major-risk cardioembolic source, ipsilateral extracranial carotid stenosis 50%, or evidence of prior cortical stroke. Additional exclusion criteria included disabling stroke (modified Rankin score 4), significant cognitive impairment (Mini-Mental State Examination 2 standard deviations below the mean for age and education), and previous nontraumatic intracranial macrohemorrhage. Local ethics committees for human research at all recruitment centers approved the study protocol, and study participation required written informed consent. SPS3 participants were eligible for the current analysis if they had an interpretable axial T2*-weighted gradient echo (GRE) sequence allowing for CMB detection as part of their baseline MRI.
Randomization and Masking
Eligible participants were randomly assigned, in a 2-by-2 factorial design, to both an antiplatelet intervention (1:1; aspirin 325mg plus clopidogrel 75mg vs aspirin 325mg plus placebo; double-blind) and a target level of systolic blood pressure control (1:1; lower [<130mmHg] vs higher ; open label). 19 Individual site staff personnel were unaware of randomization assignments, which were stored electronically at the SPS3 statistical center.
Procedure
Full study procedures have been published elsewhere. 19, 20 Briefly, participants were seen at least every 3 months for blood pressure measurement, adjustment of drug treatment, dispensing of antiplatelet drugs, and detection of adverse events. Adherence to assigned antiplatelet treatment was estimated as 94% by pill count. 17 Permanent discontinuation of assigned antiplatelet drug occurred in 30% of patients. 17 After 1 year, the mean systolic blood pressure was 138mmHg (95% confidence interval [CI] 5 137-139) in the higher target group and 127mmHg (95% CI 5 126-128) in the lower target group, with a mean difference of 11mmHg (standard deviation [SD] 5 16) at last study visit. 18 
Participant Characteristics
Patients with lacunar stroke (deficit lasting > 24 hours) or subcortical transient ischemic attack (deficit lasting < 24 hours) documented by infarct on MRI were randomized into the trial. Diabetes was defined as a history of diabetes mellitus at the time of the qualifying stroke, fasting serum glucose 120mg/dl at the time of stroke, and/or initiation of antidiabetic medications during the first 3 months of follow-up. Blood pressure at entry (baseline) was the average of 2 screening systolic blood pressure determinations, an average of 3 at first visit and of 3 at second visit 1 week later. Severity of hypertension was adjusted by adding 5mmHg for each antihypertensive medication (up to a maximum of 4) at the time of the determination. Normotensive was defined as <120mmHg, prehypertensive as 120 to < 140mmHg, stage I hypertension as 140 to < 160mmHg, and stage II hypertension as 160mmHg or more. Race and ethnicity were determined primarily by selfreport, using the 2 Census 2000 questions regarding race and Hispanic/Latino ethnicity as previously described.
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FIGURE 1: Kaplan-Meier curve for recurrent stroke by cerebral microbleed (CMB) status.
Imaging Acquisition and Analysis
Participants underwent structural brain MRI before study entry as part of their clinical management without prespecified protocol for data acquisition. Participant eligibility was determined locally with MRI scans subsequently submitted for central review. Determination of location of qualifying infarct, old subcortical infarcts, and white matter hyperintensities (WMHs)
were done centrally. 21 Old lacunar infarcts were defined as hypointense areas on fluid-attenuated inversion recovery (FLAIR) and/or T1 measuring 3mm and 15mm in maximum dimension. Hypointense lesions at the level of the anterior commissure, convexity, or midbrain were considered enlarged perivascular spaces and not classified infarcts, unless surrounded by a hyperintense halo on FLAIR. Intrarater reliability of old lacunar infarcts was assessed by having a neuroradiologist (C.B.) reevaluate a set of 75 MRIs at the end of the study, unaware of his earlier interpretations. Intrarater reliability for presence/absence of lacunas on FLAIR/T1 was good (j 5 0.64, 88% agreement). WMHs were evaluated visually on FLAIR images using Age-Related White Matter Changes (ARWMC; range 5 0-16). ARWMC scale categories were defined a priori as: 0 to 4, mild disease; 5 to 8, moderate disease; and 9 or more, severe disease. Inter-rater agreement was good-excellent on a sample of 40 MRIs (4 raters; range: j 5 0.64, 77% agreement to j 5 0.89, 95% agreement).
CMBs were rated according to the Brain Observer Microbleed Rating Scale with each CMB determined to be "certain" or "uncertain," and to be lobar (isolated to cortex/ gray white junction and/or subcortical white matter) or deep (isolated to basal ganglia gray matter, internal/external capsule, thalamus, brainstem, and/or cerebellum). 22 Total numbers of each and overall of deep and lobar CMBs (regardless of size and certainty) were then computed, and severity of disease was coded a priori as absent (0 CMBs), mild (1-2 CMBs), moderate (3-10 CMBs), or severe (>10 CMBs), and location was coded as lobar only, deep only, or mixed. 23 CMB readings were done by 1 rater (A.S.) blinded to baseline features and outcomes with excellent intrarater reliability for CMB presence on 2 separate reads of the same images separated by >12 months (n 5 55, j 5 0.82, 91% agreement), and previously reported excellent inter-rater reliability for CMB presence in a separate cohort. 24 
Outcomes
The primary outcome of interest was all stroke recurrence (first ischemic stroke or intracranial hemorrhage), and secondary outcome of interest was all-cause mortality. Ischemic stroke was clinically defined as a focal neurologic deficit of sudden onset persisting for >24 hours, and without evidence of hemorrhage on neuroimaging. Intracranial hemorrhages included those in intracerebral, subdural, epidural, and subarachnoid locations as documented on neuroimaging. A central adjudication committee that was unaware of the treatment assignments adjudicated all reported outcomes.
Statistical Analysis
Patient demographic and clinical characteristics were compared between groups in cross-sectional analyses using a chi-square test for categorical variables and a t test or analysis of variance for continuous variables. Forward and backward stepwise multivariate binomial logistic regression analyses (likelihood ratio test) were used to identify variables independently associated with CMBs. Multivariate Cox proportional hazards models were used to estimate the contribution of CMBs to risk of (1) recurrent stroke and (2) death during follow-up after adjusting for assigned treatment groups and other covariates as noted. A prespecified sensitivity analysis was also performed excluding patients with only "uncertain" CMBs. All analyses followed the intention-to-treat paradigm. All tests were 2-sided, and statistical significance was accepted at the 0.05 level. Analyses were performed with SPSS version 22.0.
Role of the Funding Source
The sponsor was not involved in the current analysis and article. However, the National Institute of Neurological Disorders and Stroke did participate in the design, data collection, primary analyses, and interpretation of the SPS3 trial.
Results
Overall, 42% of enrolled participants between 2003 and 2011 (1,278 of 3,020) had images available to assess CMBs (34% of United States/Canada enrollees, 62% of Latin America enrollees, and 48% of Spain enrollees) and were included in these analyses (Fig 1) . Participants had a mean age of 63 years (SD 5 11), were 65% male, and had histories of hypertension, diabetes, and prior stroke of 75%, 36%, and 10%, respectively. Included participants were more often Hispanic, male, with greater severity of hypertension, and with underrepresentation of smoking and renal dysfunction, but did not otherwise differ significantly with respect to baseline characteristics and MRI findings from those excluded ( Table 1) . Thirty percent (n 5 380) of the 1,278 patients had at least 1 CMB. Patient characteristics independently associated with CMBs were increasing age, male sex, Hispanic ethnicity, hypertension, higher baseline systolic blood pressure, prior lacunar stroke, and nondiabetic status compared to those with no CMB (Tables 2 and 3) . Patients with CMBs also more often had multiple old lacunar infarcts on MRI and more WMHs (see Tables 2 and 3) . Of those with CMBs, severity of disease (CMB count burden) was mild in 57% (n 5 217), moderate in 31% (n 5 118), and severe in 12% (n 5 45). Participant characteristics did not vary by severity except that patients with more severe disease were more often Hispanic and less often diabetic (Table 4 ). More severe disease was associated with more advanced CSVD (WMHs and multiple old lacunar infarcts) on MRI (see Table 4 ).
Location of CMBs was lobar only in 21% (n 5 81), deep only in 44% (n 5 167), and mixed in 35% (n 5 132). Participants with lobar only CMBs were more likely to have diabetes (at a rate proportionally similar to patients without CMBs), but otherwise did not differ from subjects with CMBs in other locations (see Table 5 ). Participants with mixed CMBs had more advanced CSVD (more CMBs, WMHs, and multiple old lacunar infarcts) on MRI.
Associations with Recurrent Stroke and Death
During a mean follow-up of 3.3 years, 100 participants (annualized rate 5 2.5% per patient-year) had a recurrent stroke (83 ischemic, 16 hemorrhagic, 1 uncertain etiology): 54 of the 898 with no CMB, 46 of the 380 with CMBs (see Fig 1) . Participants with CMBs were at increased risk of recurrent stroke (adjusted hazard ratio [HR] 5 2.1, 95% CI 5 1.4-3.1) after adjusting for assigned treatment groups and clinical risk factors for recurrent stroke in the SPS3 trial (male sex, black race, diabetes, and prior symptomatic lacunar stroke or transient ischemic attack 25 . Risk of recurrent stroke (adjusted HR 5 2.3, 95% CI 5 1.5-3.6) was not appreciably changed when the patients with hemorrhagic strokes (11 in no CMB group and 5 in CMB group) were excluded, nor when the 57 patients with only "uncertain" CMBs were excluded (adjusted HR 5 2.0, 95% CI 5 1.3-3.1). After adjusting for multiple old lacunar infarcts on MRI (>1) and WMHs (ARWMC groups; coded as 0-4, 5-8, and 91) as well as assigned treatment group and clinical risk factors, participants with CMBs remained at increased risk of stroke (adjusted HR 5 1.9, 95% CI 5 1.2-2.9). Adjusting for old lacunar infarcts on MRI and WMHs (ARWMC score) as continuous variables instead of as categorical variables in this same model did not affect the increased risk of stroke with CMBs observed (adjusted HR 5 1.9, 95% CI 5 1.2-2.9). Recurrent stroke risk appeared highest in patients with >10 CMBs and lobar only CMBs (Table 6, Fig 2) ; however, there was inadequate power to detect significant differences between CMB burden or location subgroups after excluding patients without CMBs from the analysis. Given the few number of hemorrhagic strokes, we were unable to carry out any meaningful analyses for this outcome in isolation. All-cause mortality risk was unaffected by CMBs (adjusted HR 5 1.2, 95% CI 5 0.8-2.0; Table 6 ).
Effect of Randomized Interventions
Overall, in our subgroup of SPS3 participants with adequate MRI sequences for CMB detection, more aggressive blood pressure lowering resulted in a statistically significant reduction in stroke recurrence (HR 5 0.6, 95% CI 5 0.4-0.9) but not all-cause mortality (HR 5 0.8, 95% CI 5 0.5-1.3; Fig 3) . Dual antiplatelet therapy with aspirin and clopidogrel did not reduce stroke recurrence compared to aspirin alone (HR 5 1.0, 95% CI 5 0.7-1.5), whereas all-cause mortality was increased in patients assigned dual antiplatelet therapy (HR 5 2.3, 95% CI 5 1.4-3.7; see Fig 3) . Aggressive blood pressure lowering significantly reduced risk of stroke recurrence in patients with CMBs (HR 5 0.5, 95% CI 5 0.3-0.9) but not patients without CMBs (HR 5 0.7, 95% CI 5 0.4-1.3); however, the difference in the magnitude of the effect was statistically insignificant (interaction, p 5 0.34). When assessing patients with moderate-severe CMB burden (3 CMBs), aggressive blood pressure lowering significantly reduced risk of stroke (HR 5 0.2, 95% CI 5 0.1-0.8), with a trend suggesting that there may exist a different treatment effect on risk of recurrent stroke in those with moderate-severe disease compared to patients without CMBs (interaction, p 5 0.087).
No effect on all-cause mortality was detected in patients with CMBs (HR 5 0.9, 95% CI 5 0.4-1.8) or patients without CMBs (HR 5 0.8, 95% CI 5 0.5-1.5; interaction, p 5 0.99; see Fig 3) . Risk of stroke recurrence did not differ for those assigned dual antiplatelet therapy versus aspirin alone among patients with CMBs (HR 5 1.2, 95% CI 5 0.7-2.2) and those without CMBs (HR 5 0.9, 95% CI 5 0.5-1.5; interaction, p 5 0.45). There was no strong suggestion that the effect of dual antiplatelet therapy in those with moderate-severe CMB burden (HR 5 1.9, 95% CI 5 0.8-4.6) differed from those with no CMBs (interaction, p 5 0.16). Dual antiplatelet therapy appeared not to increase all-cause mortality in patients with CMBs (HR 5 1.8, 95% CI 5 0.8-3.8) in contrast to those without CMBs (HR 5 2.7, 95% CI 5 1.4-5.1); however, the effect modification was not statistically significant (interaction, p 5 0.41; see Fig 3) .
Discussion
In this large and well-characterized cohort of patients with recent lacunar stroke, we found CMBs to be highly prevalent, and associated with overrepresentation of hypertensive disease and underrepresentation of diabetes mellitus, as well as an independent predictor of stroke recurrence. In this subgroup of SPS3 participants who underwent MRI sequences allowing for CMB detection, intensive blood pressure control was associated with a statistically significant reduction in recurrent stroke (HR 5 0.6, 95% CI 5 0.4-0.9), but there was no statistically significant interaction with the presence of CMBs.
Similar to previous reports, we found a high prevalence of CMBs in lacunar stroke patients. 3 The observed 30% prevalence rate of CMBs is similar to that found in other lacunar stroke cohorts from Caucasian populations. 6, 7 Our results demonstrate that even within a cohort restricted to well-characterized symptomatic CSVD, CMBs are strongly associated with advanced hypertensive disease and MRI markers of CSVD. The mechanism underlying the lower prevalence of diabetes mellitus in patients with lacunar stroke who have CMBs on MRI-a novel observation-is, however, uncertain. One plausible explanation is that in patients with diabetes, lacunar strokes result more frequently from branch orifice atheromatous disease [26] [27] [28] rather than hypertensive arteriopathy, the latter being the predominant vascular pathology underlying strictly deep/mixed CMBs. 2 Hence, the perceived inverse association may result from diabetic subjects in this population having a different non-CMBinducing vascular pathology contributing to their lacunar strokes, which we hypothesize to be branch orifice atheromatous disease. The presence of CMBs on baseline MRI was associated with a 2-fold increased risk of stroke during followup. This association remained unchanged after excluding patients with incident intracerebral hemorrhage (ICH). Similarly, a recent systematic review/meta-analysis reported a CMB-related 1.8-fold increase in risk of recurrent ischemic stroke after ischemic stroke/transient ischemic attack. 11 Observing a nearly identical relationship within a sample of lacunar stroke that is independent of other MRI markers of advanced CSVD suggests that the association between CMBs and recurrent ischemic stroke goes beyond CMBs simply marking underlying CSVD and is hypothesis generating. One possibility is that extravasated hemosiderin, which has been reported to migrate through perivascular spaces, inducing an intense inflammatory reaction, could contribute to the pathogenesis of vascular compromise and future cerebral vascular injury. 29 Alternatively, CMBs on MRI may mark higher CSVD severity that is not represented by the other MRI markers. The observed trend for higher rates of recurrent stroke in patients with strictly lobar CMBs also suggests a possible synergistic relationship between hypertensive arteriopathy and CAA, possibly by way of impaired cerebral vascular reactivity. 30 As our current therapeutic strategies are insufficient in mitigating recurrent ischemic stroke risk in patients with lacunar stroke, these hypotheses need to be explored further in future experimental and clinical studies, as they could potentially lead to novel therapeutic targets to halt CSVD and related neuronal injury. 31 Conversely, CMBs were not predictive of all-cause mortality within our cohort, suggesting that underlying CSVD might have confounded their previously reported associations with mortality in broader populations. [12] [13] [14] Our low number of ICHs during follow-up negated the possibility of any meaningful analysis confined to risk of incident ICH. To our knowledge, our reported findings are the first assessing the effect of secondary stroke preventative therapies in patients with CMBs within the context of a randomized controlled trial. In contrast to prior observational studies demonstrating a greater degree of adverse events with the use of antithrombotic agents in patients with CMBs, 16 we did not observe a statistically significant treatment interaction between CMB presence and dual versus single antiplatelet therapy. Accordingly, our results caution against deriving firm conclusions regarding conservative antithrombotic therapy regimens in patients with CMBs solely from observational data that can be prone to residual confounding, particularly because most ischemic stroke patients with CMBs have higher future absolute rates of ischemic events, rather than hemorrhagic ones. 11 Although no statistically significant treatment interactions were observed between the tested blood pressure targets and CMB presence, there did exist a trend for patients with CMBs to have greater therapeutic effect with intensive blood pressure control, particularly in patients with moderate-severe CMB burden. However, we restate that the apparent difference in response to blood pressure lowering according to CMB status was not statistically significant, rendering our observations hypothesis-generating and requiring further exploration in larger samples. Our results were limited by the unavailability of MRI sequences allowing for CMB assessment in all SPS3 trial participants, which was largely center-dependent according to localized MRI sequence protocols. This may have introduced selection bias into our sample. For instance, included participants within our sample were more often Hispanic, compared to the larger SPS3 population. Moreover, the distribution of SPS3 recruitment sites across the Americas and Spain limits the generalizability of our findings to the worldwide population, such as East Asian populations that have a high prevalence of CSVD and may be more prone to ICH. 32 The SPS3
trial occurred between 2003 and 2011, and technological advancements in CMB detection since then also may limit generalizability. Importantly, the nonstandardization of GRE sequence acquisition parameters and the unavailability of data on these parameters or MRI field strengths, which were never captured, for inclusion into our multivariate analyses are major limitations that may have resulted in heterogeneous CMB detection rates across the various recruitment centers and confounded our results. Our observation of greater severity of white matter damage on MRI in patients with mixed CMBs could be confounded by this subgroup by definition only including patients with multiple CMBs (2), whereas those categorized as strictly lobar or deep can include patients with a single CMB. We categorized patients with "uncertain" CMBs as CMB positive due to similarities observed in their baseline characteristics to patients with "certain" CMBs, which is imperfect. Reassuringly, however, sensitivity analyses excluding patients with only "uncertain" CMBs did not alter our findings. We rated WMH using a visual ARWMC rating scale, rather than volumetric measurements. Although visual scales are more clinically applicable, it is possible that the absence of volumetric measurements limited our ability to appropriately adjust for degree of WMH in our analyses. A final limitation is that our sample was underpowered to appropriately assess risk by CMB burden and topography, and treatment interactions in the CMB burden and topography subgroups, as well as for the outcome of ICH.
Results from this largest well-defined cohort of lacunar stroke suggest that CMBs are highly prevalent in patients with lacunar stroke and an independent predictor of stroke recurrence. Accordingly, the presence of CMBs in patients with lacunar stroke likely represents a more aggressive form of CSVD in need of efficacious therapeutic strategies. Until such therapies become available, our data suggest that it would be reasonable to reinforce guideline recommendations suggesting intensive blood pressure reduction to systolic blood pressure < 130mmHg in lacunar stroke patients, particularly in the presence of CMBs on MRI.
